Skip to main content

Table 4 Multivariate linear regression analysis for predictors of ziv-aflibercept anatomical response after 6 months

From: Switching to ziv-aflibercept in resistant diabetic macular edema non responsive to ranibizumab injection

   

P value

95% Confidence Interval for B

B

Beta

Lower Bound

Upper Bound

No of injection

2.034

0.054

0.667

−7.404

11.471

BCVA before injection

−24.807

−0.097

0.471

−93.435

43.822

Final BCVA after 6 months

1.694

0.008

0.947

− 49.466

52.855

Duration

1.335

0.129

0.237

−0.906

3.577

HbA1c

−3.894

−0.071

0.536

−16.437

8.648

pre switch CMT

−0.007

− 0.018

0.911

− 0.140

0.125

CMT after one month

−0.107

− 0.188

0.291

−0.307

0.094

CMT after three month

0.645

0.953

0.001*

0.423

0.866

  1. No Number, BCVA Best corrected visual acuity, CMT Central macular thickness, HbA1c Hemoglobin A1c, *statistically significant